Peregrine Capital Management LLC Makes New Investment in Omnicell, Inc. $OMCL

Key Points

• Peregrine Capital bought 106,059 shares of Omnicell in Q4 (~$4.8M), giving it roughly 0.24% ownership as institutional investors now hold about 97.7% of the stock.
• EVP Corey J. Manley sold 7,405 shares at an average price of $34.69 on March 16, reducing his holding by 7.11%; corporate insiders own about 2.52% of Omnicell.
• Omnicell missed quarterly EPS ($0.40 vs. $0.47 estimate), issued Q1 2026 guidance of $0.26–$0.36 and FY2026 guidance of $1.65–$1.85, while analysts have a "Moderate Buy" consensus and an average target price of $59.

Peregrine Capital Management LLC bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 106,059 shares of the company's stock, valued at approximately $4,804,000. Peregrine Capital Management LLC owned approximately 0.24% of Omnicell at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Omnicell by 71.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company's stock worth $6,343,000 after acquiring an additional 58,193 shares in the last quarter. Round Rock Advisors LLC raised its stake in Omnicell by 53.4% during the fourth quarter. Round Rock Advisors LLC now owns 21,088 shares of the company's stock worth $955,000 after acquiring an additional 7,339 shares in the last quarter. First Horizon Corp raised its stake in Omnicell by 54.6% during the fourth quarter. First Horizon Corp now owns 1,597 shares of the company's stock worth $72,000 after acquiring an additional 564 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Omnicell by 4.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,536 shares of the company's stock worth $749,000 after acquiring an additional 741 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Omnicell by 219.4% during the fourth quarter. SG Americas Securities LLC now owns 20,547 shares of the company's stock worth $931,000 after acquiring an additional 14,114 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Insider Activity

In other news, EVP Corey J. Manley sold 7,405 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the transaction, the executive vice president owned 96,717 shares of the company's stock, valued at $3,355,112.73. This represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.52% of the stock is owned by corporate insiders.

Omnicell Stock Performance

Omnicell stock opened at $37.37 on Friday. The business has a 50 day moving average of $36.83 and a 200-day moving average of $39.13. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The company has a market capitalization of $1.70 billion, a P/E ratio of 934.48, a P/E/G ratio of 1.30 and a beta of 0.85.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The firm had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. During the same period in the prior year, the company earned $0.60 EPS. The business's quarterly revenue was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities research analysts predict that Omnicell, Inc. will post 0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. UBS Group set a $60.00 target price on Omnicell and gave the stock a "buy" rating in a research note on Friday, March 13th. KeyCorp raised Omnicell from a "sector weight" rating to an "overweight" rating and set a $60.00 target price for the company in a research note on Wednesday, January 7th. Zacks Research raised Omnicell from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Weiss Ratings downgraded Omnicell from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, March 2nd. Finally, Piper Sandler reissued an "overweight" rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Omnicell has an average rating of "Moderate Buy" and a consensus target price of $59.00.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.